Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2023 (Report Date: July 31, 2023)
Headquarters: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the cover page content.
Exhibits Submitted:
- Exhibit 99.1: Quarterly Activities/Appendix 4C Cash Flow Report
Investors must refer to Exhibit 99.1 for detailed financial data.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. The document serves primarily as a cover sheet incorporating the Quarterly Activities report by reference.
Guidance, Outlook, and Risks
Management Commentary: None provided in the cover text.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).
Risks/Contingencies: No specific risks or unusual items are listed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Quarterly Activities and Cash Flow data, as the cover page contains no figures.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements for potential equity issuance plans.
- Confirm the company's development stage status and its implications for revenue generation timelines.
- Check the Appendix 4C Cash Flow Report for liquidity runway given the lack of revenue disclosure.